| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
4,4-Dimethyl-2-cyclopenten-1-one targets cellular thiols and proteins through Michael addition reactions. The compound's α,β-unsaturated ketone moiety allows it to undergo conjugate addition with nucleophiles such as thiol groups in cysteine residues. This reactivity underlies its potential biological activities including anti-inflammatory and anticancer effects. The compound may target signaling pathways regulated by thiol modifications, such as the NF-κB pathway. The methyl groups at the 4 position may influence its reactivity and selectivity. Further research is needed to identify its specific molecular targets.
|
|---|---|
| ln Vitro |
4,4-Dimethyl-2-cyclopenten-1-one kills tumor cells (HL-60, HSC-2) only. In HSC-2, HSC-3, HSG, HL-60, HGF, and normal cells (HPC), 4,4-Dimethyl-2-cyclopenten-1-one shows CC50 (50% cytotoxic concentration) values of 43.8 μg/mL, 152 μg/mL, 118 μg/mL, 14.0 μg/mL, 177 μg/mL, and 123 μg/mL, respectively[1].
In vitro studies have demonstrated that 4,4-Dimethyl-2-cyclopenten-1-one exhibits potential anti-inflammatory and anticancer activities. The compound's ability to undergo Michael addition reactions with thiols has been characterized. Its effects on cell signaling pathways such as NF-κB have been evaluated in cell-based assays. The compound's cytotoxicity against cancer cell lines has been assessed using cell viability assays. These in vitro findings support its potential applications in anti-inflammatory and anticancer research. |
| ln Vivo |
In vivo studies of 4,4-Dimethyl-2-cyclopenten-1-one are limited, as the compound is primarily used as a research chemical and chemical intermediate. Its anti-inflammatory and anticancer activities suggest potential for in vivo evaluation in models of inflammation and cancer. Cyclopentenone derivatives have been studied in animal models for their therapeutic potential. However, comprehensive in vivo studies specifically targeting 4,4-Dimethyl-2-cyclopenten-1-one are not well documented in the available literature. Further research is needed to fully characterize its in vivo efficacy and safety.
|
| Enzyme Assay |
In vitro enzyme and receptor binding assays for 4,4-Dimethyl-2-cyclopenten-1-one typically involve testing its reactivity with thiols and its effects on enzyme activity. The compound's ability to modify cysteine residues in proteins is assessed using biochemical methods such as mass spectrometry or fluorescence labeling. Enzyme inhibition assays are performed for potential targets such as kinases or proteases. Anti-inflammatory activity is assessed by measuring inhibition of NF-κB activation or pro-inflammatory cytokine production. All assays are performed with appropriate controls and standardized protocols.
|
| Cell Assay |
In vitro cell-based assays for 4,4-Dimethyl-2-cyclopenten-1-one involve culturing cells to evaluate its anti-inflammatory and anticancer activities. Cells are treated with varying concentrations of the compound and cell viability is assessed using MTT or similar colorimetric assays. For anti-inflammatory studies, cells are stimulated with inflammatory stimuli and cytokine production is measured by ELISA. NF-κB activation is assessed using reporter gene assays or by measuring phosphorylation of IκBα. For anticancer studies, apoptosis is quantified using flow cytometry with Annexin V/PI staining. All experiments are performed in triplicate with appropriate controls.
|
| Animal Protocol |
In vivo animal experiments for 4,4-Dimethyl-2-cyclopenten-1-one would be conducted to evaluate its anti-inflammatory and anticancer activities. For anti-inflammatory studies, animals with induced inflammation would be treated and inflammatory markers measured. For anticancer studies, tumor-bearing animals would be treated and tumor growth monitored. Parameters assessed would include body weight, organ weights, and histopathology. Control groups receiving vehicle alone would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines. Comprehensive in vivo studies are not well documented in the available literature.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 4,4-Dimethyl-2-cyclopenten-1-one reflect its nature as a small cyclopentenone compound. It has a molecular weight consistent with its formula C7H10O. As a small lipophilic molecule, it can cross biological membranes readily. The compound's α,β-unsaturated ketone moiety makes it reactive and subject to metabolism through conjugation with glutathione. Complete pharmacokinetic profiling including half-life, clearance, volume of distribution, and bioavailability would require further systematic studies using appropriate analytical methods such as high-performance liquid chromatography-mass spectrometry.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 4,4-Dimethyl-2-cyclopenten-1-one has been evaluated in the context of its use as a research chemical. As an α,β-unsaturated ketone, it can react with cellular thiols and may cause cytotoxicity. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile. The compound's reactivity suggests it should be handled with caution.
|
| References |
|
| Additional Infomation |
According to reports, perilla contains 4,4-dimethyl-2-cyclopenten-1-one, and there is relevant data.
4,4-Dimethyl-2-cyclopenten-1-one (CAS# 22748-16-9) is a cyclopentenone derivative with the molecular formula C7H10O. It features a cyclopentene ring with a ketone at the 1 position and two methyl groups at the 4 position. The compound is used as a chemical intermediate in organic synthesis. Cyclopentenones are known for various biological activities including anti-inflammatory and anticancer properties through Michael addition reactions with cellular thiols. 4,4-Dimethyl-2-cyclopenten-1-one is intended for research use only and is not for human therapeutic use. |
| Molecular Formula |
C7H10O
|
|---|---|
| Molecular Weight |
110.15
|
| Exact Mass |
110.073
|
| CAS # |
22748-16-9
|
| PubChem CID |
140955
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.903
|
| Boiling Point |
155.1ºC at 760mmHg
|
| Melting Point |
174-175 °C
|
| Flash Point |
46ºC
|
| Vapour Pressure |
3.09mmHg at 25°C
|
| Index of Refraction |
1.457
|
| LogP |
1.541
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
143
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1(C)C=CC(=O)C1
|
| InChi Key |
YVFVCSCZJJGBAK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H10O/c1-7(2)4-3-6(8)5-7/h3-4H,5H2,1-2H3
|
| Chemical Name |
4,4-dimethylcyclopent-2-en-1-one
|
| Synonyms |
4,4-Dimethylcyclopent-2-enone; 4,4-Dimethyl-2-cyclopenten-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (907.85 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (22.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (22.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (22.70 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.0785 mL | 45.3926 mL | 90.7853 mL | |
| 5 mM | 1.8157 mL | 9.0785 mL | 18.1571 mL | |
| 10 mM | 0.9079 mL | 4.5393 mL | 9.0785 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
